Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Keros Therapeutics, Inc.NASDAQ: KROS
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 40.6% from a year ago
Other current liabilities stood at $3.46M at the end of Q1 FY2026, down 40.6% from a year earlier and down 43.2% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- Other current liabilities amounted to 1.1% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -40.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.09M USD
- Year-over-year change
- -42.3%
- 4-year CAGR
- +24.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.09M | -42.3% |
| FY2024 | 2024-12-31 | 10.55M | +1.6% |
| FY2023 | 2023-12-31 | 10.38M | +86.6% |
| FY2022 | 2022-12-31 | 5.56M | +115.8% |
| FY2021 | 2021-12-31 | 2.58M | — |
Other Current Liabilities vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's Mar 2026 other current liabilities of $3.46M is the 8th highest of the 10 companies compared; the peer median is $8.02M.
- Its year-over-year change of -40.6% is the 5th highest of 8, against a peer median of -13.5%.
- Other current liabilities amounts to 1.1% of total assets for KROS, versus a peer median of 3.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $48.5M | +42.8% | +51.7% | 9.6% | |
| Mar 2026 | $42.49M | +2514.9% | +90.9% | 8.0% | |
| Mar 2026 | $23.59M | -53.8% | -32.0% | 6.9% | |
NAGENiagen Bioscience Inc | Mar 2026 | $8.52M | — | — | 7.4% |
| Mar 2026 | $8.02M | — | — | 2.2% | |
| Mar 2026 | $7.91M | +146.3% | +74.6% | 3.5% | |
| Mar 2026 | $6.27M | -50.8% | — | 3.2% | |
| Mar 2026 | $3.46M | -40.6% | +3.1% | 1.1% | |
| Mar 2026 | $2.2M | -13.5% | +619.0% | 0.5% | |
| Mar 2026 | $1.59M | -67.0% | +66.3% | 0.6% | |
| Peer median (excluding KROS) | $8.02M | -13.5% | +70.4% | 3.5% | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 230.04M | 279.05M | 331.15M | 559.93M | 287.42M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 18.2M | 841K | 1.09M | 4.46M | 6.37M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 210K | 276K | 1M | 1.48M | 2.4M |
| Total Current Assets | 251.44M | 285.77M | 347.29M | 588.89M | 315.43M |
| Property, Plant & Equipment (Net) | 2.4M | 17.57M | 19.47M | 23.49M | 21.14M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 1.21M | 1.45M | 1.45M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.41M | 3.45M | 2.05M | 2.06M | 0 |
| Total Non-current Assets | 3.81M | 21.01M | 22.73M | 26.99M | 22.59M |
| Total Assets | 255.25M | 306.78M | 370.03M | 615.89M | 338.02M |
| Account Payables | 3.65M | 3.34M | 5.45M | 4.6M | 1.97M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 110K | 50K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.58M | 5.56M | 10.38M | 10.55M | 6.09M |
| Total Current Liabilities | 11.85M | 16.55M | 24.37M | 27.45M | 20.41M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 231K | 12.81M | 13.44M | 16.88M | 14.48M |
| Total Liabilities | 12.08M | 29.36M | 37.81M | 44.33M | 34.89M |
| Common Stock | 2K | 2K | 3K | 4K | 4K |
| Retained Earnings | (123.76M) | (228.43M) | (381.43M) | (568.78M) | (481.77M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 243.17M | 277.42M | 332.21M | 571.55M | 303.13M |
| Total Debt | 1.09M | 13.27M | 14.44M | 18.86M | 16.88M |
| Net Debt | (228.95M) | (265.78M) | (316.7M) | (541.07M) | (270.53M) |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.